April 16, 2014 5:12 AM ET


Company Overview of Oramed Pharmaceuticals Inc.

Company Overview

Oramed Pharmaceuticals, Inc., a development stage pharmaceutical company, is engaged in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company’s product portfolio includes ORMD0801, an oral insulin capsule that is in Phase II clinical trials for the treatment of diabetes; and ORMD0901, an analog for GLP-1 gastrointestinal hormone, which is in pre-clinical trials. Its portfolio of product candidates is based on intellectual property that allows for the protection of proteins and polypeptides in the stomach, and for their absorption through the gastrointestinal wall. The company was formerly known as...

Hi-Tech Park 2/4


PO Box 39098

Jerusalem,  91390


Founded in 2002


972 2 566 0001


972 2 566 0004

Key Executives for Oramed Pharmaceuticals Inc.

Chief Executive Officer
Age: 39
Total Annual Compensation: $259.7K
Chief Financial Officer
Age: 39
Total Annual Compensation: $98.4K
Chief Operating Officer and Vice President of Business Development
Age: 43
Total Annual Compensation: $48.4K
Chief Medical & Technology Officer and Director
Age: 73
Total Annual Compensation: $188.4K
Compensation as of Fiscal Year 2013.

Oramed Pharmaceuticals Inc. Key Developments

Intellectual Property Department of Hong Kong Grants Patent for Oral Administration of Insulin of Oramed

Oramed Pharmaceuticals Inc. announced that the Intellectual Property Department of Hong Kong has granted the company's patent for its invention, titled Methods and Compositions for Oral Administrations of Proteins.

Oramed Pharmaceuticals Inc. Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-11-2014 08:30 AM

Oramed Pharmaceuticals Inc. Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-11-2014 08:30 AM. Venue: Loews Miami Beach Hotel, Miami, Florida, United States. Speakers: Nadav Kidron, Chief Executive Officer, President and Executive Director.

Oramed Pharmaceuticals Inc. to Present Results from its Phase 2a FDA trial on ORMD-0801

Oramed Pharmaceuticals Inc. announced that it will be presenting detailed results from its recently completed Phase 2a FDA trial on ORMD-0801, its orally ingestible insulin capsule at the 2014 GTC Diabetes Summit taking place from April 23-25, 2014, in Boston, Massachusetts, USA. This was a randomized, double-blind, placebo-controlled Phase 2a study designed to assess the safety and tolerability of multiple bedtime doses of the ORMD-0801 oral insulin formulation in adult Type 2 diabetes patients inadequately controlled with diet alone or diet and metformin. Preliminary results were announced by the company on January 30(th) of this year.

Similar Private Companies By Industry

Company Name Region
Koffolk (1949) Ltd. Middle East/Africa
Abital Pharma Pipelines Ltd. Middle East/Africa
cCam Medical Ltd. Middle East/Africa
Moebius Medical Ltd. Middle East/Africa
Mapi Pharma Ltd. Middle East/Africa

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Oramed Pharmaceuticals Inc., please visit www.oramed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.